Cite
MLA Citation
Joao V Alessi et al.. “Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status.” Journal for immunotherapy of cancer, vol. 8, no. 2, 2020, p. . http://access.bl.uk/ark:/81055/vdc_100127560602.0x00003d